The cannabis industry is growing, as local initiatives to facilitate medicinal or recreational use expand even in the face of federal resistance. State regulatory regimes are creating a patchwork of experiments that may inform a path forward for a federal regulatory regime, whether or not cannabis is removed from Schedule I of the Controlled Substances Act (CSA).

Join scholars and practitioners at this year’s Food and Drug Law Journal Symposium to discuss the ambiguities and prospects for the federal regulation of cannabis. This academic symposium explores the often overlooked implications of FDA regulation in relation to the emerging marijuana product industry.  Topics include FDA’s relevance to edibles and infused products and cannabis medical product development, as well as the interplay of the agency’s jurisdiction with DEA, DOJ, and the states.

Venue Sponsor

Register Now

Industry & Firms

  • $199 for nonmembers


  • $49 for nonmembers


  • $49 for nonmembers


  • $49 for nonmembers


  • full-time students only


subject to change

November 2, 2018

8:00 AM
Registration and Continental Breakfast

8:30 AM
Welcome and Announcements
Judy Rein
, Director, Publications, FDLI

8:40 – 9:30 AM
History and Overview of Cannabis Regulation

Presenters: Erika Lietzan, Associate Professor, University of Missouri School of Law | Speaker’s Slides
  Lewis A. Grossman, Professor of Law, Washington College of Law, American University | Speaker’s Slides

9:30 – 10:20 AM
Canadian Liberalization and the Global Market

Presenter: Patrick Moen, General Counsel, Privateer Holdings

10:20 – 10:30 AM
Networking and Coffee Break

10:30 – 11:45 AM
Edibles and Infused Products

Authors: Deborah Shelton, Practice Group Leader, Food & Drug Law Practices, McCarter & English, LLP
  Daniel L. Flint, Ph.D Associate, McCarter & English, LLP | Speaker’s Slides
  “Points to Consider When Seeking Approval of Cannabis Edibles as Botanical Drugs”
  Kellsi Booth, Attorney, Wake Law Group (Los Angeles, CA)
  “The Mysteries of Medibles: Exploring the Regulation of Marijuana-Infused Products Intended for Medical Use”
Discussant: James O’Reilly, University of Cincinnati | Speaker’s Slides
Moderator: Daniel Dwyer, Partner, Kleinfeld Kaplan & Becker LLP

11:45 – 1:15 PM
Luncheon Keynote
Welcome: Amy Comstock Rick, President & CEO, FDLI
Aidan Hampson
, Program Officer, Clinical Research Grants Branch, Division of Therapeutics & Medical Consequences, Special Content Expert on Cannabis, National Institute on Drug Abuse, National Institutes of Health | Speaker’s Slides
Introduced by Joseph A. Page, Professor Emeritus, Georgetown University Law Center and Faculty Advisor, Food and Drug Law Journal

1:15 – 2:30 PM
Medical Product Pathways

Authors: Heike Newman, Senior Regulatory Manager, University of Colorado
  “Marijuana Research in Colorado 2018”
  Micha Mesure, Wake Law Group (Los Angeles, CA) | Speaker’s Slides
  “Using Foreign Data for Cannabis Derived Drug: Israel as a Guideline to Satisfy FDA Requirements and Comply with Federal Regulation”
Discussant: Linda Bentley, Member, Mintz, Levin LLP
Moderator: Sandra Retzky, Johns Hopkins University and FDA

2:30 – 2:45 PM
Networking and Coffee Break

2:45 – 4:15 PM
Strategies and Constraints for Moving Forward

Authors: Srikumaran Melethil, Professor Emeritus, Schools of Pharmacy and Medicine, University of Missouri-Kansas City
  “State Regulation of the Commerce and Uses of Marijuana, a Federal Schedule I Drug”
  Tami Wahl, Principal, Tami L. Wahl | Speaker’s Slides
  “A Modern, Forward-Thinking State-Federal Framework”
  Eric Lindblom, Director, Tobacco Control and Food & Drug Law, O’Neill Institute for National & Global Health Law, Georgetown University Law Center
  “How FDA Could Use Its Existing Authorities to Make State Legalization of Cannabis for Medical or Broader Purposes More Safe and Effective”
Discussant: Erica M. Jackson, Partner, K & L Gates LLP
Moderator: Robert Giddings, Attorney, Hutchison PLLC and Chair, FDLI Editorial Advisory Board, Food and Drug Law Journal
Closing Remarks: Amy Comstock Rick, President & CEO, FDLI


4:15 – 5:00 PM
FDLI Membership Meeting: Cannabis-Derived Products and Future Programming
FDLI invites Symposium participants to join FDLI members and staff in a brainstorming session led by FDLI President & CEO Amy Rick to share ideas for FDLI’s future engagement in this emerging area.

5:00 – 6:00 PM



Call for Abstracts

FDLI thanks all who participated in the Call for Abstracts.

Continuing Legal Education

FDLI applies for CLE credits in Ohio, Pennsylvania, and Virginia. These CLE approvals may also be honored by other states; please check with your bar association for guidance. The CLE credits will be posted as they are granted and you can request to be notified when approval is received.

Pennsylvania: approved for 5.5 CLE credit hours
Ohio: approved for 5.50 CLE credit hours

Location and Overnight Accommodations


Covington & Burling LLP
850 10th St. NW
Washington, DC 20001

Overnight Accommodations

The following hotels are within walking distance of the meeting location:

The Liaison Capitol Hill, 415 New Jersey Ave NW
Hyatt Regency Washington on Capitol Hill, 400 New Jersey Ave NW
Washington Court Hotel, 525 New Jersey Ave NW
Kimpton George Hotel, 15 E St NW

Please contact the Conference Department with any accessibility requirements or dietary restrictions, or for other questions.